The Elman Retina Group has announced the availability of Encelto, the first FDA-approved therapy for Macular Telangiectasia Type 2 (MacTel). This cutting-edge encapsulated cell therapy provides continuous protein release to preserve retinal health, now accessible to patients at Elman’s specialized clinics across the Baltimore and Maryland area.
Welcome to the newly redesigned Elman Retina Group website! While our online look has changed to provide a better digital experience, our commitment to world-class retinal care remains exactly the same.
Elman Retina Group is pleased to announce that Dr. Daniel Brill, M.D., dual-fellowship trained in vitreoretinal surgery and uveitis, is now accepting new patients at our Baltimore-area offices.
Dr. Michael J. Elman presented cutting-edge research findings on advanced retinal therapeutics at the prestigious Macula Society annual meeting.
